| Name | Title | Contact Details |
|---|
Thoele Dental Laboratories Inc is a Waite Park, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InCyte Pathology is the premier provider of anatomic diagnostic services in the Northwest. Our state-of-the-art facility based in Spokane Valley, Washington, is owned and operated by pathologists dedicated to providing patients with comprehensive
Pathology and Cytology Lab is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medytox Solutions, Inc. develops and delivers cutting-edge testing and reporting technology and systems, providing an affordable and superior service to medical providers. In turn, our medical provider clients are able to provide better and more cost-effective patient care. Medytox offers its clients a complete solution, with faster turnaround times and more reliable and accurate results, in a manner that is safe, secure and HIPAA-compliant in all respects. We conduct our testing on the most accurate and advanced equipment available, using proven methodologies to provide superior results, while supporting our clients with personnel, equipment and turn-key services dedicated to providing them with the latitude to offer an optimized level of enhanced patient care.
Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors. We plan to combine these personalized neoantigen-targeted therapies with current immune checkpoint modulatory approaches to improve response rates and survival in patients with solid tumors.